BACKGROUND Infection of implanted medical devices has catastrophic consequences. For cardiac rhythm devices, pre-
W
ith the increased use of implantable medical devices in orthopedic, cardiovascular, and other areas of medicine, device infection has become a major problem. Staphylococcus aureus and S. epidermidis have emerged as the most common pathogens in patients receiving medical devices, which can be difficult to treat or prevent due to antibiotic resistance (1) (2) (3) . Cardiac implantable electronic device (CIED) infection has been reported to occur in w2% of all cases, and the risk is 2% to 4% in high-risk patients (2) (3) (4) (5) (6) (7) . The treatment cost of device infection is high, with case costs of US$146,000 attributed to hospitalization, long courses of intravenous (IV) antibiotics and frequent need for system removal (4) (5) (6) (7) (8) (9) . Prevention of infection is a major concern for device implant centers, which use standard policies to optimize outcomes.
The conventional approach to prevention of device infection, based on several small randomized trials, is single pre-operative infusion of cefazolin, which is supported by guidelines (10). Incremental antibiotic measures are not supported by evidence from randomized trials (11) .
However, even though cefazolin is active against most gram-positive bacteria and some gram-negative bacteria, approximately 20% of device infections are due to organisms that are resistant to cefazolin (also referred to as "methicillin-resistant" organisms) (12) .
Because virtually all gram-positive organisms that are implicated in CIED infection are sensitive to vancomycin, and the majority are sensitive to bacitracin (13) , we hypothesized that an incremental antibiotic policy that included preprocedural infusion of both cefazolin and vancomycin, plus intraprocedural bacitracin wash followed by a 2-day course of postoperative antibiotics would reduce the 1-year risk of hospitalization for device infection as compared with conventional cefazolin alone.
Because device procedures are most frequently performed in larger centers using standard operating procedures, we considered that a cluster randomized crossover trial would be an optimal design to test whether an institutional standard policy of incremental antibiotics would reduce device infection. In this design, each institution is randomized to 1 of 2 antibiotic prophylaxis regimens, with randomized crossover between these regimens, such that institutions would switch randomly between the 2 antibiotic regimens every 6 months. We calculated that the crossover would substantially reduce the loss of power due to the cluster approach and result in substantial trial efficiency.
METHODS
TRIAL DESIGN. The design of the PADIT (Prevention of Arrhythmia Device Infection Trial) has previously been described (14) . The primary hypothesis of the PADIT trial was that an institutional policy of incremental antimicrobial prophylaxis would reduce the and at least 3 months of enrollment were complete in each period. There was a 2-to 4-week transition phase between each of the 4 study periods.
All patients at each center received the antibiotic strategy to which the center was randomized at the time, as standard procedure during each study period. Three sites were excluded from the trial early in the first period of participation because of failure to adhere to the randomized protocol (n ¼ 2) and because of insufficient patients (n ¼ 1). These exclusions were made without any knowledge by the steering committee of the treatment allocation or the number of infections at the site. One site restarted the first period after compliance with the protocol was corrected. comprehensive single-provider system (19) . The ICC in that registry was 0.015, and we assumed that both IPC and ICC in the PADIT trial would be the same. On the basis of published reports, we estimated that device infection rate would be 2.0%/year among highrisk patients receiving conventional treatment (2-7).
On the basis of these assumptions, we estimated that treatment of 100 patients for each of 4 treatment periods per site (26 sites in total) would be required to achieve 80% power of detecting a 35% relative risk reduction with a 2-sided significance level of 0.05. To allow for 4% loss to follow-up and death during follow-up, the target was to treat 10,800 patients.
The primary statistical analysis was on the highrisk cohort, and secondarily on the total patient Table 1 ). The median number of patients undergoing a procedure per treatment period per site was 110.
Twenty-one centers were tertiary care centers (75%).
The median number of operators per center was 5.5.
PATIENTS.
A total of 19,603 patients across 28 centers having device procedures were included in the data collection, of which 12,842 patients were high risk ( Figure 2 outlines the forest plot to illustrate evaluation of subgroups for treatment effect. There were no important interactions between treatment effect and baseline, cluster site of procedure, or operator characteristic (Online Table 2 ).
Infection rates analyzed by device type shows a clear gradient of risk from pacemaker to ICD to CRT, with no evidence of interaction between device type and effect of the intervention ( Table 4) . Table 3 ). For example, there was no significant difference in the proportion of infections that were due to methicillin-sensitive S. aureus, and in the proportion of infections that were polymicrobial. With respect to antimicrobial susceptibility, there was no significant difference in the proportion of organisms that were resistant to cefazolin and vancomycin between the study arms.
Multivariable analyses with adjustment of cluster and patient-level risk factors showed similar results as the primary analysis (Online Table 4 ). Ontreatment analysis including only protocolcompliant patients (all antibiotics administered, including complete infusion before skin incision) (Online Table 4 ) did not differ from the intentionto-treat analysis ( Table 3) . Adverse events were rare (0.26%), with equivalent adverse events in both arms (Online Table 5 ).
EFFECT OF USING THE CLUSTER RANDOMIZED
CROSSOVER DESIGN. The calculated ICC and IPC after conduct of the study were 0.00077 and 0.00061, respectively, using a linear mixed effects model. Previous studies have consistently reported that device infection rates are increasing as more complex procedures are undertaken in patients with a higher burden of comorbidities (20) . Greenspon et al. (20) reported infection rates from 4.2 million device surgery records in the Nationwide Inpatient Sample, wherein the infection rate was steady at 1.5% until an inflection point in 2004, when rates rose to 2.5% through 2008. The device infection rate in our study was much lower than anticipated. We included all patients treated at each center, so the lower rates
were not due to patient selection. There may have been a "Hawthorne" effect, insofar as being in a research study led centers to increase vigilance to both antibiotic adherence and surgical technique to minimize infection rate. A nonsignificant trend of reduction in infection rate over time was seen in both arms of the study (Online Table 6 Values are n/N (%) unless otherwise indicated. Infection rates were significantly different between the 3 device types (all pairwise comparisons p < 0.01). There was no interaction between device type and treatment effect.
Abbreviations as in Tables 1 and 3 . The consistent modest reduction seen across device types was not significantly different. CIED ¼ cardiac implantable electronic device;
CENTRAL ILLUSTRATION
CRT ¼ cardiac resynchronization therapy; ICD ¼ implantable cardioverter-defibrillator. 
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